Skip to main content

Table 5 Prognostic factors for time to next treatment

From: Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

  Univariate analysis Multivariate analysis
Covariate P HR (95% CI) P HR (95% CI)
Sex (ref: Male) 0.0014 0.835 (0.747–0.933) 0.0013 0.825 (0.733–0.928)
Age (ref: < 75 years old) 0.0023 1.374 (1.120–1.686)
Histotype (ref: Other)
 LMS 0.5114 0.955 (0.831–1.097)
 DLPS 0.0068 1.357 (1.088–1.692)
 MPNST 0.3703 1.154 (0.843–1.580)
 SS 0.8580 0.983 (0.811–1.191)
 UPS 0.0375 1.243 (1.013–1.525)
 Grade (ref: < 3) < 0.0001 1.417 (1.258–1.596) < 0.0001 1.372 (1.218–1.546)
 Number of metastatic sites (ref: 1) 0.1175 1.118 (0.972–1.285)
 Liver metastasis (ref: no) 0.1436 1.103 (0.967–1.259)
 Locoregional treatment (ref: no) < 0.0001 0.496 (0.442–0.556) < 0.0001 0.487 (0.432–0.550)
 Clinical trial in first line (ref: no) 0.6453 1.048 (0.859–1.277)
 Anthracycline in first line (ref: no) < 0.0001 0.756 (0.674–0.847)
 Polychemotherapy in first line (ref: no) < 0.0001 0.729 (0.651–0.815) < 0.0001 0.743 (0.660–0.836)
  1. DLPS dedifferentiated liposarcomas, LMS leiomyosarcomas, MPNST malignant peripheral nerve sheath sarcomas, SS synovial sarcomas, UPS undifferentiated pleomorphic sarcomas